Immunotherapy Drugs Market – Top Companies, Business Growth & Investment Opportunities, Share and Forecasts 2025

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Fri, 15 Jan 2021 05:14:33 / Comserve Inc. / — The report offers overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

The immunotherapy drugs market is anticipated to record a CAGR of 13% during the forecast period. The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies. Furthermore, immunotherapy is widely used in cancer treatment

For instance, over the past decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune-based therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. Thus, the rise in the number of diseases and associated disorders is among the major primary reasons for the growth of this immunotherapy drugs market.

Click Here to Download Sample Report >>

Key Market Trends

Cancer is Expected to Hold the Major Share in the Therapy Area Segment

– Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. This cancer prevalence is expected to be the same in the coming years, which is helping the market to grow.
– There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators.�??
– These therapies are used for many types of cancer and their advanced stages. The side-effects of cancer immunotherapy vary, depending upon the immunotherapy being used. Some of the popular immunotherapy drugs are Rituxan, Yervoy, Adcetris, and Zevalin, among several others.�??
– The growth of immunotherapies in developed markets is high, due to increased R&D, with better government policies for supporting clinical trials through findings and campaigns, in order to raise awareness regarding several kinds of cancer.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.

According to the estimates of the American Cancer Society, in 2018, there would be 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.�??

In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and rising prevalence of chronic and lifestyle disorders are the primary factors propelling the immunotherapy market in the United States. In March 2019, Roche’s Tecentriq in combination with Abraxane received U.S.FDA accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer. Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer.

Competitive Landscape

The immunotherapy drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches R&D, expansions to gain competitive advantage. In August 2019, U.S.FDA approved pexidartinib (TURALIO(TM), Daiichi Sankyo) capsules for adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Some of the major players of the market are AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

Request For Full Report >>

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Adoption of Targeted Therapy over Traditional Therapy
4.2.2 Emergence of Biosimilars
4.2.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
4.2.4 Rising Demand for Monoclonal Antibodies
4.3 Market Restraints
4.3.1 High Cost of Immunotherapy Treatment
4.3.2 High Attrition Rate in the Product Development Cycle
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Drug
5.1.1 Monoclonal Antibodies
5.1.2 Vaccines Preventive Vaccines Therapeutic Vaccines
5.1.3 Checkpoint Inhibitors
5.1.4 Interferons Alpha and Beta
5.1.5 Interleukins
5.1.6 Other Types of Drugs
5.2 By Therapy Area
5.2.1 Cancer
5.2.2 Autoimmune and Inflammatory Diseases
5.2.3 Infectious Diseases
5.2.4 Other Therapy Areas
5.3 By End User
5.3.1 Hospitals/Clinics
5.3.2 Cancer Research Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 AstraZeneca plc
6.1.4 Bristol-Myers Squibb
6.1.5 F. Hoffmann-La Roche AG
6.1.6 GlaxoSmithKline plc
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Novartis AG
6.1.10 UbiVac


The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Hina Miyazu

Shibuya Data Count
Email: [email protected]
Tel: + 81 3 45720790

The post Immunotherapy Drugs Market – Top Companies, Business Growth & Investment Opportunities, Share and Forecasts 2025 appeared first on Comserveonline.


Is there a problem with this press release? Contact the source provider Comtex at [email protected]. You can also contact MarketWatch Customer Service via our Customer Center.

The MarketWatch News Department was not involved in the creation of this content.